Mike Blecker, Scientific Director of Medical Affairs of Solid Tumors at Incyte, shared on LinkedIn:
“Big step forward for treating pancreatic cancer!
Huge win for patients! This is just the beginning, with >4 DOZEN KRAS agents in clinical trials, the field will continue to evolve and based on past experience with targeted therapies, my personal belief is we’ll be able to sequence and combine these agents with newer, novel MOA agents, further extending response for all patients with KRAS mutations.”
Title: FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
Author: OncLive Staff
You can also read: FDA Approves Daraxonrasib: First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer
